Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng

Computers in Biology and Medicine

Volumn 43, Issue 6, 2013, Pages 786-797

  Sathishkumar, Natarajan ^a   Karpagam, Veerappan ^a,b   Sathiyamoorthy, Subramaniyam ^a   Woo, Min J ^a   Kim, Yeon Ju ^a   Yang, Deok Chun ^a  

^a Kyung Hee University   (South Korea)

^b Department of Biochemistry   (India)

Author keywords

ADME; EGFR; Ginsenosides; Insilco; Panax ginseng; Pharmacophore

Indexed keywords

ADME; EGFR; GINSENOSIDES; INSILCO; PANAX GINSENG; PHARMACOPHORES;

AMINO ACIDS; BINDING ENERGY; CELL DEATH; CELL MEMBRANES; CELL PROLIFERATION; DISEASES; LEAD COMPOUNDS; MOLECULAR MODELING; PHARMACODYNAMICS;

ENZYMES;

CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GINSENOSIDE;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DATA BASE; ENZYME ACTIVE SITE; GINSENG; IC 50; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; GINSENOSIDES; HUMANS; MOLECULAR DOCKING SIMULATION; PANAX; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84877721218     PISSN: 00104825     EISSN: 18790534     Source Type: Journal    
DOI: 10.1016/j.compbiomed.2013.02.020     Document Type: Article

References (59)

1. Carter G.T. ChemInform abstract: natural products and pharma 2011: strategic changes spur new opportunities. ChemInform 2012, 43. no-no.
2. Mehta R.G., Murillo G., Naithani R., Peng X. Cancer chemoprevention by natural products: how far have we come?. Pharm. Res. 2010, 27:950-961.
3. Scaglione F., Pannacci M., Petrini O. The standardised G115Panax ginseng CA Meyer extract: a review of its properties and usage. Evidence-based Integr. Med. 2005, 2:195-206.
4. Christensen L.P. Ginsenosides: chemistry, biosynthesis, analysis, and potential health effects. Advances in Food and Nutrition Research 2008, 1-99. Academic Press, Chapter 1. L.T. Steve (Ed.).
5. Leung K., Wong A. Pharmacology of ginsenosides: a literature review. Chin. Med. 2010, 5:20.
6. S. Sathiyamoorthy, J.G. In, B.S. Lee, W.S. Kwon, D.U. Yang, J.H. Kim, D.C. Yang, Insilicoanalysis for Expressed Sequence Tags from Embryogenic Callus and Flower Buds of Panax ginseng CA Meyer, (2010).
7. Chen C.-f., Chiou W.-f., Zhang J.-t. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. Acta Pharmacol. Sin. 2008, 29:1103-1108.
8. Park J., Rhee D., Lee Y. Biological activities and chemistry of saponins from <i>Panax ginseng</i> C. A. Meyer. Phytochemi. Rev. 2005, 4:159-175.
9. Choi K.-t. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol. Sin. 2008, 29:1109-1118.
10. Ernst E. Panax ginseng: an overview of the clinical evidence. J. Ginseng. Res. 2010, 34:259-263.
11. Herbst R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol.Biol.Phys. 2004, 59:S21-S26.
12. Ward W.H.J., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Green L.R. Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48:659-666.
13. Janmaat M.L., Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncol. 2003, 8:576-586.
14. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
15. Bates S.E., Fojo T. Epidermal growth factor receptor inhibitors: a moving target?. Clin. Cancer Res. 2005, 11:7203-7205.
16. Chrysogelos S.A., Yarden R.I., Lauber A.H., Murphy J.M. Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res. Treat. 1994, 31:227-236.
17. Franklin W.A., Veve R., Hirsch F.R., Helfrich B.A., Bunn P.A. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin. Oncol. 2002, 29:3-14.
18. Gershtein E.S., Ermilova V.D., Kuz'mina Z.V., Kuzlinskii N.E., Letiagin V.P. Expression of epidermal growth factor receptors and their ligands in malignant tumors of the breast. Vestn. Ross. Akad. Med. Nauk. 1996, 15-19.
19. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19:6102-6114.
20. Harari P.M., Huang S.M. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin. Radiat. Oncol. 2002, 12:21-26.
21. Karlin J.D., Nguyen D., Yang S.X., Lipkowitz S. Epidermal growth factor receptor expression in breast cancer. J. Clin. Oncol. 2005, 23:8118-8119.
22. KLIJN J.G.M., BERNS P.M.J.J., SCHMITZ P.I.M., FOEKENS J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev. 1992, 13:3-17.
23. Paul M.K., Mukhopadhyay A.K. Tyrosine kinase-role and significance in cancer. Int. J. Med. Sci. 2004, 1:101-115.
24. Saxena R., Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med. Res. Rev. 2010.
25. Ferguson K.M. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys. 2008, 37:353-373.
26. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137:1293-1307.
27. Fry D.W. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Expert Opin. Invest. Drugs 1994, 3:577-595.
28. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267:1782-1788.
29. Madhusudan S., Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 2004, 37:618-635.
30. Shawver L.K., Slamon D., Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
31. Pasha F.Ahmad, Muddassar M., Srivastava A.Kumar, Cho S.Joo In silico QSAR studies of anilinoquinolines as EGFR inhibitors. J. Mol. Model. 2010, 16:263-277.
32. Gundla R., Kazemi R., Sanam R., Muttineni R., Sarma J.A.R.P., Dayam R., Neamati N. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. J. Med. Chem. 2008, 51:3367-3377.
33. Gupta A.K., Bhunia S.S., Balaramnavar V.M., Saxena A.K. Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors. SAR QSAR Environ. Res. 2011, 22:239-263.
34. Zhu L.L., Hou T.J., Chen L.R., Xu X.J. 3D QSAR analyses of novel tyrosine kinase inhibitors based on pharmacophore alignment. J. Chem. Inf. Comput. Sci. 2001, 41:1032-1040.
35. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4:187-217.
36. Smellie A., Teig S.L., Towbin P. Poling: promoting conformational variation. J. Comput. Chem. 1995, 16:171-187.
37. Chen C.-Y., Chen C.Y.-C. Insights into designing the dual-targeted HER2/HSP90 inhibitors. J. Mol. Graphics Modell. 2010, 29:21-31.
38. Neria E., Fischer S., Karplus M. Simulation of activation free energies in molecular systems. J. Chem. Phys. 1996, 105:1902-1921.
39. Huang N., Shoichet B.K., Irwin J.J. Benchmarking sets for molecular docking. J. Med. Chem. 2006, 49:6789-6801.
40. Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discovery 2002, 1:882-894.
41. Yun T.K. Brief introduction of Panax ginseng C.A. Meyer. J. Korean Med. Sci. 2001, 16(Suppl):S3-S5.
42. Hartshorn M.J., Verdonk M.L., Chessari G., Brewerton S.C., Mooij W.T.M., Mortenson P.N., Murray C.W. Diverse, high-quality test set for the validation of protein-ligand docking performance. J. Med. Chem. 2007, 50:726-741.
43. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28:235-242.
44. Ma Y., Wen W., Liu J. Effects of ginsenoside Rg3 on Cx26 gene expression and gap junctional intercellular communication in human breast cancer cell line MCF-7. Zhongliu Yanjiu Yu Linchuang 2011, 23:91-93.
45. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277:46265-46272.
46. Cosconati S., Forli S., Perryman A.L., Harris R., Goodsell D.S., Olson A.J. Virtual screening with AutoDock: theory and practice. Expert Opin. Drug Discovery 2010, 5:597-607.
47. Sathishkumar N., Sathiyamoorthy S., Ramya M., Yang D.U., Lee H.N., Yang D.C. Molecular docking studies of anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins with ginsenosides from Panax ginseng. J. Enzyme Inhib. Med. Chem. 2012, 27:685-692.
48. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
49. Kansal N., Silakari O., Ravikumar M., Three A. Dimensional pharmacophore modeling for KDR and Tie-2 receptor tyrosine kinase inhibitors and virtual screening for new multikinase inhibitors. QSAR Comb. Sci. 2009, 28:1130-1147.
50. Zhang J., Liu G., Tang Y. Chemical function-based pharmacophore generation of selective κ-opioid receptor agonists by catalyst and phase. J. Mol. Model. 2009, 15:1027-1041.
51. Kalyaanamoorthy S., Chen Y.-P.P. Structure-based drug design to augment hit discovery. Drug Discovery Today 2011, 16:831-839.
52. Kim K.-H., Kim N.D., Seong B.-L. Pharmacophore-based virtual screening: a review of recent applications. Expert Opin. Drug Discovery 2010, 5:205-222.
53. C. Gopi Mohan, T. Gandhi, D. Garg, R. Shinde, Computer-assisted methods in chemical toxicity prediction, Mini Reviews in Medicinal Chemistry, 7 499-507.
54. Moroy G., Martiny V.Y., Vayer P., Villoutreix B.O., Miteva M.A. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discovery Today 2012, 17:44-55.
55. Dearden J.C. In silico prediction of aqueous solubility. Expert Opin. Drug Discovery 2006, 1:31-52.
56. Hou T., Wang J., Zhang W., Wang W., Xu X. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr. Med. Chem. 2006, 13:2653-2667.
57. Wagner A.B. SciFinder Scholar 2006: an empirical analysis of research topic query processing. J. Chem. Inf. Model. 2006, 46:767-774.
58. Wang Y., Bolton E., Dracheva S., Karapetyan K., Shoemaker B.A., Suzek T.O., Wang J., Xiao J., Zhang J., Bryant S.H. An overview of the PubChem BioAssay resource. Nucleic Acids Res. 2010, 38:D255-D266.
59. Dougherty U., Mustafi R., Wang Y., Musch M., Wang C.-Z., Konda V., Kulkarni A., Hart J., Dawson G., Kim K., Yuan C.-S., Chang E., Bissonnette M. American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement. Alter. Med. 2011, 11:111.